ZA201901321B - Tablet compositions - Google Patents

Tablet compositions

Info

Publication number
ZA201901321B
ZA201901321B ZA2019/01321A ZA201901321A ZA201901321B ZA 201901321 B ZA201901321 B ZA 201901321B ZA 2019/01321 A ZA2019/01321 A ZA 2019/01321A ZA 201901321 A ZA201901321 A ZA 201901321A ZA 201901321 B ZA201901321 B ZA 201901321B
Authority
ZA
South Africa
Prior art keywords
tablet compositions
pyridin
trifluoromethyl
amino
tablet
Prior art date
Application number
ZA2019/01321A
Other languages
English (en)
Inventor
S Bhat Sreenivas
Burnside Scott
Parikh Darshan
Gu Chong-Hui
Altaf Syed
Original Assignee
Celgene Corp
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Agios Pharmaceuticals Inc filed Critical Celgene Corp
Publication of ZA201901321B publication Critical patent/ZA201901321B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2019/01321A 2016-09-07 2019-03-01 Tablet compositions ZA201901321B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384643P 2016-09-07 2016-09-07
US201762535162P 2017-07-20 2017-07-20
PCT/US2017/050202 WO2018048847A1 (en) 2016-09-07 2017-09-06 Tablet compositions

Publications (1)

Publication Number Publication Date
ZA201901321B true ZA201901321B (en) 2023-12-20

Family

ID=59895401

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/01321A ZA201901321B (en) 2016-09-07 2019-03-01 Tablet compositions

Country Status (16)

Country Link
US (3) US11389454B2 (enExample)
EP (1) EP3509570A1 (enExample)
JP (2) JP2019529534A (enExample)
KR (1) KR102498693B1 (enExample)
CN (2) CN109715143A (enExample)
AU (1) AU2017324844B2 (enExample)
BR (1) BR112019004356A2 (enExample)
CA (1) CA3036053A1 (enExample)
CL (1) CL2019000573A1 (enExample)
CO (1) CO2019002092A2 (enExample)
EC (1) ECSP19015828A (enExample)
IL (1) IL265126B2 (enExample)
MX (1) MX392941B (enExample)
SG (1) SG11201901873PA (enExample)
WO (1) WO2018048847A1 (enExample)
ZA (1) ZA201901321B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092915A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092906A1 (en) * 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020239759A1 (en) * 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
US20220401450A1 (en) * 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
WO2024008138A1 (zh) * 2022-07-07 2024-01-11 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的药物组合

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771339B1 (en) * 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
WO2015018060A1 (en) 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3302442B1 (en) * 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물

Also Published As

Publication number Publication date
IL265126A (enExample) 2019-04-30
CN109715143A (zh) 2019-05-03
JP2022191265A (ja) 2022-12-27
JP2019529534A (ja) 2019-10-17
BR112019004356A2 (pt) 2019-05-28
CO2019002092A2 (es) 2019-05-31
US11389454B2 (en) 2022-07-19
AU2017324844B2 (en) 2023-05-11
CL2019000573A1 (es) 2019-07-19
US20220323447A1 (en) 2022-10-13
IL265126B1 (en) 2023-08-01
KR102498693B1 (ko) 2023-02-10
KR20190045199A (ko) 2019-05-02
US20180064715A1 (en) 2018-03-08
ECSP19015828A (es) 2019-03-29
NZ751112A (en) 2024-03-22
CN120501712A (zh) 2025-08-19
CA3036053A1 (en) 2018-03-15
SG11201901873PA (en) 2019-03-28
EP3509570A1 (en) 2019-07-17
AU2017324844A1 (en) 2019-03-21
US20240335450A1 (en) 2024-10-10
WO2018048847A1 (en) 2018-03-15
IL265126B2 (en) 2023-12-01
MX392941B (es) 2025-03-24
JP7487270B2 (ja) 2024-05-20
MX2019002697A (es) 2019-10-04

Similar Documents

Publication Publication Date Title
MX392941B (es) Composiciones para comprimidos.
DK3833670T3 (da) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorphenyl)-2-methylpyrimidin-4(3h)-on-derivater og lignende forbindelser som PTPN11- (SHP2) hæmmere til cancerbehandling
IL269586A (en) Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
PH12020550792A1 (en) Compounds useful for inhibiting cdk7
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
PH12017550028A1 (en) Solid forms of an ask1 inhibitor
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX389260B (es) Sales co-formadoras de (2s,3s)-7-fluoro-2-(4-fluorofenil)-3-(1-metil-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carboxilato de metilo y sus metodos de preparacion.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
HUE060152T2 (hu) 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk
ZA201803748B (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl) pyridin-3-yl)oxy)benzonitrile and processes of preparation
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
GEAP201914215A (en) Pharmaceutical composition containing pyridylamino acetic acid compound
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
IL252844B (en) Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
EP3541796A4 (en) 4 - ((6- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
EP3541799A4 (en) PROCESSES FOR THE PREPARATION OF 4 - ((6- (2- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-HYDROXY-3- (5-MERCAPTO-1H-1,2,4-TRIAZOL-1- YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE
DK3456712T3 (da) Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP3541801A4 (en) 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
MX2019005504A (es) Potenciadores de bmp.
EP3541800A4 (en) PROCESSES FOR THE PREPARATION OF 4 - ((6- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-HYDROXY-3- (5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL) PROPYL ) PYRIDIN-3-YL) OXY) BENZONITRILE
EA201990640A1 (ru) Таблеточные композиции
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H